Related Experiment Video

Updated: Aug 19, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Epidermal growth factor receptor inhibitors and colorectal cancer

Jeffrey A Meyerhardt1, Charles S Fuchs

  • 1Dana-Farber Cancer Institute, Brigham and Women's Hospital Boston, Massachusetts 02115, USA. jmeyerhardt@partners.org

Oncology (Williston Park, N.Y.)
|February 3, 2005
PubMed

Insights

Targeting epidermal growth factor receptor (EGFR) is crucial for colorectal cancer treatment. Cetuximab, an EGFR-targeting monoclonal antibody, is approved for metastatic disease refractory to irinotecan.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) is vital for cell growth, differentiation, and survival.
  • Targeting EGFR is a key therapeutic strategy in colorectal cancer (CRC).

Purpose of the Study:

  • To discuss the role of targeted agents against EGFR in colorectal cancer treatment.
  • To review the efficacy of cetuximab, a monoclonal antibody targeting EGFR.
  • To explore other targeted agents, including monoclonal antibodies and tyrosine kinase inhibitors.

Main Methods:

  • Review of existing literature on EGFR-targeted therapies in colorectal cancer.
  • Analysis of clinical data for cetuximab in metastatic colorectal cancer.
  • Discussion of the mechanisms of action for various EGFR inhibitors.

Main Results:

  • Cetuximab (Erbitux) is approved for EGFR-positive metastatic colorectal cancer refractory to irinotecan (Camptosar).
  • EGFR-targeted therapies represent an important advancement in colorectal cancer treatment.
  • Ongoing research explores additional monoclonal antibodies and tyrosine kinase inhibitors targeting EGFR.

Conclusions:

  • Targeted therapy against EGFR, exemplified by cetuximab, offers a valuable treatment option for specific colorectal cancer patient populations.
  • Further investigation into diverse EGFR-targeting agents is warranted to optimize colorectal cancer management.
  • Personalized medicine approaches focusing on EGFR status are critical for effective colorectal cancer therapy.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...